Update: Acute coronary syndromes (V). Personalized antiplatelet therapy

Paul A. Gurbel, Rahil Rafeedheen, Udaya S. Tantry

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


It is well established that high on-treatment platelet reactivity to adenosine diphosphate during clopidogrel therapy is an independent risk factor for ischemic event occurrences in a postpercutaneous coronary intervention patients. However, the precise role of platelet function testing remains debated. Platelet function testing to ensure optimal platelet inhibition has been recommended by some authorities to improve outcomes in patients treated with clopidogrel. Recent prospective, randomized trials of personalized antiplatelet therapy have failed to demonstrate a benefit of platelet function testing in improving outcomes. In this review article, we discuss the mechanisms responsible for clopidogrel nonreponsiveness, recent trials of platelet function testing, and other new developments in the field of personalized antiplatelet therapy.

Original languageEnglish (US)
Pages (from-to)480-487
Number of pages8
JournalRevista española de cardiología (English ed.)
Issue number6
StatePublished - Jun 1 2014


  • Determinación de genotipo
  • Genotyping
  • Personalized antiplatelet therapy
  • Platelet function testing
  • Pruebas de la función plaquetaria
  • Thrombosis
  • Tratamiento antiagregante plaquetario personalizado
  • Trombosis

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Update: Acute coronary syndromes (V). Personalized antiplatelet therapy'. Together they form a unique fingerprint.

Cite this